|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: LUNESTA
Summary for Tradename: LUNESTA
|
|
Latest news for LUNESTASleeping the night away24 May 2013, 6:29 pm Merck Insomnia Drug Is Safe Only in Lower Doses, Panel Says22 May 2013, 5:54 pm Sunovion Pharmaceuticals Inc. Presents Data Showing 12 Months of Latuda® (lurasidone HCl) Treatment Resulted in Higher ...21 May 2013, 12:00 pm US sleeping products market led by Pfizer's Advil PM20 May 2013, 8:00 pm Sunovion Pharmaceuticals Inc. Announces Data Showing Latuda® (lurasidone HCl) was Associated with Low Rates of Weight ...20 May 2013, 3:10 pm Merck Insomnia Drug Safer at Lower Dose, FDA Staff Says20 May 2013, 9:17 am Sunovion Presents Results from a One-year, Large Simple Safety Study of BROVANA® (arformoterol tartrate) Inhalation ...20 May 2013, 9:00 am Sunovion to Present Three Posters on Results of One-year Large Simple Safety Study for BROVANA® (arformoterol tartrate ...16 May 2013, 9:00 am Mentally ill in N.C. jails without treatment options5 May 2013, 8:16 pm Courtesy of Yahoo News | ||||||||||||
Clinical Trials for: LUNESTAEfficacy & Safety of Eszopiclone (Lunesta) in Nursing Home Patients Status: Completed Condition: Sleep Deprivation The Effects of Eszopiclone and Lexapro on Prefrontal Glutamate and GABA in Depression With Anxiety and Insomnia Status: Completed Condition: Depression; Anxiety; Insomnia Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban Status: Terminated Condition: Insomnia; Nicotine Dependence Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone Status: Completed Condition: Parkinson's Disease; Insomnia Eszopiclone in the Treatment of Insomnia and Fibromyalgia Status: Completed Condition: Fibromyalgia; Insomnia Eszopiclone for the Treatment of Posttraumatic Stress Disorder Status: Recruiting Condition: Posttraumatic Stress Disorders Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder Status: Completed Condition: Insomnia; Generalized Anxiety Disorder A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150) Status: Completed Condition: Insomnia Brain Mechanisms and Targeting Insomnia in Major Depression Status: Active, not recruiting Condition: Major Depressive Disorder; Insomnia Hypnotics to Improve Polysomnography Yield: Eszopiclone vs Ramelteon? Status: Completed Condition: Obstructive Sleep Apnea Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sunovion Pharms Inc | LUNESTA | eszopiclone | TABLET; ORAL | 021476 | Dec 15, 2004 | RX | No | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sunovion Pharms Inc | LUNESTA | eszopiclone | TABLET; ORAL | 021476 | Dec 15, 2004 | RX | No | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sunovion Pharms Inc | LUNESTA | eszopiclone | TABLET; ORAL | 021476 | Dec 15, 2004 | RX | No | 6,319,926*PED | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sunovion Pharms Inc | LUNESTA | eszopiclone | TABLET; ORAL | 021476 | Dec 15, 2004 | RX | No | 6,444,673*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: LUNESTA
| Drugname | Dosage | Strength | RLD | Submissiondate |
| eszopiclone | Tablets | 1 mg, 2 mg and 3 mg | Lunesta | 12/15/2008 |
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc